Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours
Authors:
Open Access
- 5 April 2019
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 10 (27) , 2586-2606
Abstract
Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2 -mutant mammary tumoursKeywords
This publication has 46 references indexed in Scilit:
- A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib ToxicityPLOS ONE, 2013
- A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast CancerClinical Cancer Research, 2010
- Differential expression analysis for sequence count dataGenome Biology, 2010
- Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachmentNature, 2009
- Understanding the Warburg Effect: The Metabolic Requirements of Cell ProliferationScience, 2009
- Twist1-Mediated Adriamycin-Induced Epithelial-Mesenchymal Transition Relates to Multidrug Resistance and Invasive Potential in Breast Cancer CellsClinical Cancer Research, 2009
- TopHat: discovering splice junctions with RNA-SeqBioinformatics, 2009
- Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling PathwayCancer Research, 2009
- Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fateBMC Genomics, 2008
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsProceedings of the National Academy of Sciences, 2008